HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Neutralizing Antibodies

Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Also Known As:
Antibodies, Neutralizing; Antibody, Neutralizing; Neutralizing Antibody
Networked: 5525 relevant articles (387 outcomes, 416 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Montefiori, David C: 42 articles (08/2015 - 03/2002)
2. Mascola, John R: 32 articles (12/2015 - 05/2003)
3. Morris, Lynn: 21 articles (05/2015 - 03/2002)
4. Haynes, Barton F: 20 articles (08/2015 - 06/2006)
5. Seaman, Michael S: 19 articles (11/2015 - 07/2008)
6. Konishi, Eiji: 18 articles (11/2015 - 01/2003)
7. Nabel, Gary J: 17 articles (08/2015 - 11/2004)
8. Stamatatos, Leonidas: 17 articles (06/2015 - 01/2003)
9. Whitehead, Stephen S: 16 articles (12/2015 - 10/2004)
10. Overbaugh, Julie: 16 articles (07/2015 - 01/2006)

Related Diseases

1. Infection
2. Neoplasms (Cancer)
01/01/2015 - "Subcutaneous LLC tumors in mice treated with TGF-β neutralizing antibody exhibited fewer γH2AX foci after irradiation and significantly greater tumor growth delay in combination with fractionated radiation. "
10/01/2011 - "Measles virus (MV) is a promising vector for cancer therapy and multivalent vaccination, but high prevalence of pre-existing neutralizing antibodies may reduce therapeutic efficacy, particularly following systemic administration. "
10/01/2008 - "Moreover, PE-NP-S was shown to be much weaker in inducing vascular leakage syndrome in mice than Mut-I. The LD(50) of PE-NP-S was about 4-fold higher than that of Mut-I. Remarkably, PE-NP-S was of low immunogenicity in development of anti-PE neutralizing antibodies in vivo and was less susceptible to inactivation by anti-PE neutralizing antibodies compared with Mut-I. In conclusion, the resultant PE-NP-S possessed increased cancer therapeutic efficacy and had reduced nonspecific toxicity and immunogenicity, suggesting that it is a potential candidate in cancer therapy."
03/15/2000 - "Although adenoviruses are an attractive vehicle for gene transfer into tissues including various tumors, in vivo adenoviral administration elicits a neutralizing antibody response which eliminates or substantially reduces the efficacy of subsequent treatments. "
11/01/2007 - "Although IFNsalpha have been widely employed for the pharmacological treatment of different types of cancer, the therapeutic efficacy occasionally can be diminished by the appearance of side effects, neutralizing antibodies or tumor resistance. "
3. Multiple Sclerosis
4. Rabies (Hydrophobia)
5. Human Influenza (Influenza)

Related Drugs and Biologics

1. Antibodies
2. Vaccines
3. Interferon-beta
4. Glycoproteins (Glycoprotein)
5. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7. Antigens
8. Cytokines
9. Epitopes
10. Complement System Proteins (Complement)

Related Therapies and Procedures

1. Microspheres (Microsphere)
2. Oral Administration
3. Heterologous Transplantation (Xenotransplantation)
4. Intraperitoneal Injections
5. Ligation